Veterinary Specialty Hospital - North County

Research Type

Ethos Discovery De Novo Study

DESCRIPTION

Paclitaxel is a human chemotherapeutic that has demonstrated a broad spectrum of activity against several human and canine cancers. Previous formulations of paclitaxel have been poorly absorbed in dogs, limiting its therapeutic value. Oraxol is a novel oral formulation of paclitaxel that is combined with a second drug, Encequidar, which improves this issue of poor absorption. Preclinical studies have demonstrated safety in dogs, making Oraxol an intriguing choice for further study in cancer-bearing dogs. The data collected from this study will help to inform future studies in the treatment of canine hemangiosarcoma, a common and aggressive cancer in dogs.

ELIGIBILITY CRITERIA

• Dogs diagnosed with cancer of any kind

• Dogs weighing between 10kg (22lb) and 45kg (99lb)

• Dogs who have not received chemotherapy within 14 days of study entry

• Dogs with no significant kidney disease

• Dogs with no significant liver disease

PARTICIPATING HOSPITALS

• Massachusetts Veterinary Referral Hospital, Woburn, MA

• Peak Veterinary Referral Center, Williston, VT

• Pet Emergency & Specialty Center of Marin (PESCM), San Rafael, California

• VERC, Honolulu, HI

• Veterinary Specialty Hospital, Sorrento Valley, San Diego, CA

• Veterinary Specialty Hospital, North County, San Marcos, CA

• Wheat Ridge Animal Hospital, Wheat Ridge, CO

• WVRC – Waukesha, Waukesha, WI